Ionis Pharmaceuticals Inc (IONS) - News Archive

Ionis Pharmaceuticals Unveils Groundbreaking Research Data at ACAAI 2025 Annual Meeting As the biopharmaceutical landscape continues to evolve, Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) recently showcased promising adv...

Pioneering the Future: Ionis Pharmaceuticals’ Strategic Advances and Financial Milestones CARLSBAD, Calif. - In a significant turn of events this past quarter, Ionis Pharmaceuticals Inc. (Nasdaq: IONS) marked a notewort...

Unlocking Potential: Ionis Pharmaceuticals Pioneers New Hope for Alexander Disease In the realm of biotechnology, where innovation often dances hand in hand with the promise of transforming lives, Ionis Pharmaceuticals,...

Olezarsen: A Revolutionary Breakthrough in Treating Hypertriglyceridemia by Ionis Pharmaceuticals Hypertriglyceridemia (HTG), characterized by elevated levels of triglycerides in the blood, poses a significant health ri...

U.S. FDA Approves DAWNZERA as First RNA-Targeted Treatment for Hereditary Angioedema In a groundbreaking development for the treatment of hereditary angioedema (HAE), Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) has annou...